All You Need To Know About The New Injectable HIV Prevention Drug, Lenacapavir
A major breakthrough in HIV prevention has arrived with the approval and global rollout of Yeztugo, a long-acting injectable medication developed by Gilead Sciences. Known scientifically as lenacapavir, Yeztugo has quickly made headlines around the world following its June 2025 approval by the U.S. Food and Drug Administration (FDA).
It is the first and only HIV prevention drug that offers protection for six months with a single injection, marking a revolutionary shift from the traditional daily oral PrEP regimens.
Yeztugo is a capsid inhibitor, a new class of antiretroviral drugs that block HIV at multiple stages of its lifecycle. Unlike previous PrEP options like Truvada or Descovy, which require daily adherence, Yeztugo is administered just twice a year. Clinical trials such as PURPOSE 1 and PURPOSE 2 showed it to be 99.9% effective in preventing HIV infection, with strong results across diverse populations including young women and adolescents in sub-Saharan Africa—regions most affected by the epidemic.
Health experts and global organizations have lauded the new drug as a public health milestone. The World Health Organization (WHO) recently endorsed lenacapavir as a recommended HIV prevention method. Its longer dosing interval helps overcome major challenges such as medication fatigue, missed doses, and stigma associated with daily pills.
While Yeztugo holds massive promise, one of the primary concerns has been its price tag. In the United States, the drug costs around $28,000 per person per year. However, Gilead has taken steps to improve global access. The company has partnered with the Global Fund to donate up to 2 million doses to low- and lower-middle-income countries over the next three years. It has also granted royalty-free licenses to six generic manufacturers to ensure affordable production and distribution in the Global South.
Initial rollout plans include several African countries such as South Africa, Kenya, and Uganda, where HIV prevalence remains high. Governments and global health partners are now working to put in place the necessary infrastructure, including training healthcare workers and strengthening follow-up systems to monitor adherence and effectiveness.
Despite its advantages, Yeztugo is not without logistical hurdles. Healthcare systems must adapt to biannual injection schedules, ensure regular HIV testing, and monitor potential drug resistance, especially in cases where patients might already be unknowingly infected.
Nevertheless, the optimism surrounding Yeztugo is substantial. With ongoing applications for regulatory approval in Europe, Brazil, Canada, Australia, and several African nations, and research into even longer-lasting injections, Yeztugo could dramatically reduce HIV transmission rates globally.
In summary, Yeztugo is more than just a new drug—it’s a transformational tool in the fight against HIV/AIDS. If equitably deployed, it could help rewrite the future of HIV prevention and move the world closer to ending the epidemic.
